- Home
- STSS vs ENSC Comparison
STSS vs ENSC Comparison
Compare STSS & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- ENSC
- Stock Information
- Founded
- STSS 2017
- ENSC 2003
- Country
- STSS United States
- ENSC United States
- Employees
- STSS N/A
- ENSC N/A
- Industry
- STSS Medical/Dental Instruments
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- ENSC Health Care
- Exchange
- STSS Nasdaq
- ENSC Nasdaq
- Market Cap
- STSS 3.3M
- ENSC 2.9M
- IPO Year
- STSS 2022
- ENSC N/A
- Fundamental
- Price
- STSS $0.02
- ENSC $3.29
- Analyst Decision
- STSS
- ENSC
- Analyst Count
- STSS 0
- ENSC 0
- Target Price
- STSS N/A
- ENSC N/A
- AVG Volume (30 Days)
- STSS 282.3M
- ENSC 4.9M
- Earning Date
- STSS 05-13-2025
- ENSC 05-12-2025
- Dividend Yield
- STSS N/A
- ENSC N/A
- EPS Growth
- STSS N/A
- ENSC N/A
- EPS
- STSS N/A
- ENSC N/A
- Revenue
- STSS N/A
- ENSC $5,210,031.00
- Revenue This Year
- STSS N/A
- ENSC N/A
- Revenue Next Year
- STSS N/A
- ENSC N/A
- P/E Ratio
- STSS N/A
- ENSC N/A
- Revenue Growth
- STSS N/A
- ENSC 133.58
- 52 Week Low
- STSS $0.01
- ENSC $1.62
- 52 Week High
- STSS $18.15
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- STSS 29.62
- ENSC 55.92
- Support Level
- STSS $0.02
- ENSC $3.02
- Resistance Level
- STSS $0.04
- ENSC $4.85
- Average True Range (ATR)
- STSS 0.01
- ENSC 0.40
- MACD
- STSS 0.02
- ENSC 0.27
- Stochastic Oscillator
- STSS 22.20
- ENSC 51.70
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.